Division of Orthodontics and Dentofacial Orthopedics, Eastman Institute for Oral Health, University of Rochester, Rochester, NY, USA.
Department of Dentistry, Eastman Institute for Oral Health, University of Rochester, Rochester, NY, USA.
Orthod Craniofac Res. 2021 May;24(2):206-213. doi: 10.1111/ocr.12428. Epub 2020 Oct 18.
The role of thyroxine administration on orthodontically induced tooth movement and/or inflammatory root resorption remains unclear. The aim was to assess the influence of thyroxine administration on orthodontically induced tooth movement and/or inflammatory root resorption. The study protocol was registered in PROSPERO (CRD42020164151). An electronic search of indexed databases was conducted without time or language restrictions up to and including May 2020. The following eligibility criteria were imposed: (a) original prospective controlled clinical studies and/or experimental studies on animal models; (b) subjects undergoing orthodontic therapy with fixed appliances; (c) presence of a control group [orthodontic tooth movement without thyroxine administration]; and (d) intervention: orthodontic tooth movement with thyroxine administration. Review articles, commentaries, letters to the editor, case reports/series, studies with no control group, cross-sectional studies, retrospective studies and studies where thyroxine was administered along with other interventions such as calcitonin and prostaglandins were excluded. Quality of available evidence and risk of bias within studies were assessed. Any disagreements were resolved via consensus discussions. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, 8 animal studies were included. Four studies reported that thyroxine administration increases the rate of orthodontic tooth movement; 3 studies did not show a significant difference. Three studies showed that thyroxine administration decreases orthodontically induced inflammatory root resorption; 2 studies found no significant difference. The risk of bias among studies was high. In conclusion, the influence of thyroxine administration on orthodontic tooth movement and/or orthodontically induced inflammatory root resorption in animal models remains unclear.
甲状腺素给药在正畸牙齿移动和/或炎症性根吸收中的作用尚不清楚。目的是评估甲状腺素给药对正畸牙齿移动和/或炎症性根吸收的影响。研究方案已在 PROSPERO（CRD42020164151）中注册。对索引数据库进行了无时间和语言限制的电子检索，截止日期为 2020 年 5 月。实施了以下纳入标准：（a）正在进行正畸治疗的固定矫治器的原始前瞻性对照临床试验和/或动物模型实验研究；（b）存在对照组[无甲状腺素给药的正畸牙齿移动]；（c）干预措施：甲状腺素给药的正畸牙齿移动。排除综述文章、评论、给编辑的信、病例报告/系列、无对照组的研究、横断面研究、回顾性研究以及甲状腺素与其他干预措施（如降钙素和前列腺素）联合给药的研究。评估了可用证据的质量和研究内的偏倚风险。任何分歧都通过共识讨论来解决。根据系统评价和荟萃分析的首选报告项目，纳入了 8 项动物研究。四项研究报告甲状腺素给药增加了正畸牙齿移动的速度；三项研究未显示出显著差异。三项研究表明甲状腺素给药减少了正畸诱导的炎症性根吸收；两项研究发现无显著差异。研究中的偏倚风险很高。总之，甲状腺素给药对动物模型中正畸牙齿移动和/或正畸诱导的炎症性根吸收的影响尚不清楚。
